PathogenDx Expands Reach of Its Patented Multiplexed Molecular Testing Technology, Bringing It to the Clinical, Food and Agriculture Sectors
Company's Novel "Dynamic Dimensional Detection" Array Technology Delivers Unprecedented Performance in Multiplexing, Turn-Around Time, Throughput and Cost Per Test
- The Company's proprietary D3 Array™ features a flexible, open, lattice-like architecture that is rich with highly accessible target-probe binding sites.
- Consequently, the duplex pairing hybridization reaction is rapid at room temperature and delivers high sensitivity and specificity results to labs and their clients.
- Additionally, our D3 Array™ is a more flexible, higher throughput and cost-effective approach than a series of multiplex qPRC/PCR assays.
- Lux Diagnostics CEO and Founder Dr. Jonathan Goss said, "PathogenDx D3 Array™ provides the best-of-both-worlds alternative.